BioCopy-Keyimage-06-T-Cell.jpg

Fast and reliable lead discovery for HLA binding.

Next-level screening for T-cell therapy

With the novel, patented T-cell therapy screening technology, BioCopy will accelerate and improve T-cell therapy development. It is one of the few companies worldwide who can support targeted therapy development for both pathways (B-cell and T-cells) of the immune system.

Rainer Böhm

Former Chief Commercial and Medical Affairs Officer at Novartis Pharma and Member of the Board of Directors at BioCopy